Harpoon Therapeutics (NASDAQ:HARP – Get Free Report) and LianBio (NASDAQ:LIAN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Profitability This table compares Harpoon Therapeutics and LianBio’s […]
Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Free Report) have received a consensus recommendation of “Hold” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year […]
Merck Completes Acquisition of Harpoon Therapeutics, Inc pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 , an investigational delta-like ligand 3 targeting T-cell engager
.
Merck (MRK) announced the completion of the acquisition of Harpoon Therapeutics, Inc. (HARP). Harpoon is now a wholly-owned subsidiary of the company. Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.